Metropolis Healthcare Limited (METROPOLIS) Financial Results — Revenue ₹16

Investor Takeaways

Revenue reached ₹16 Cr, reflecting 16% YoY growth as highlighted in the filing

EBITDA margins improved year-on-year, indicating margin expansion

⚠️ No specific risks identified in this filing

Overall Tone: Positive based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹16 Cr	16%
Net Profit	Not available	Not available
EBITDA	Not available	Improved YoY
EPS	Not available	Not available
OPM	Not available	Not available

What Changed

The filing indicates that Metropolis Healthcare Limited recorded approximately 16% year-on-year revenue growth in Q1FY27, amounting to ₹16 Cr. This growth was primarily driven by expansion in patient volume and a favorable product mix, with the TruHealth Wellness and Specialty segments contributing significantly. EBITDA margins demonstrated improvement on a year-on-year basis, while remaining stable when compared quarter-on-quarter. The company emphasized operational momentum, citing sustained demand and pricing resilience in core segments. The financial performance reflects a positive shift in top-line trajectory, supported by strategic segmental performance and cost discipline. No commentary on profitability or EPS was included in the provided summary or current fundamentals.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Metropolis Healthcare Limited	71.76	Not available	Not available	10,964.53
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

The company’s P/E ratio of 71.76 is comparable to Divi's Laboratories (72.41) but significantly higher than Sun Pharmaceutical (41.28), suggesting market expectations of higher future growth. However, peer companies demonstrate stronger profitability metrics, with Sun Pharmaceutical reporting ROE and ROCE above 15% and 20% respectively. Metropolis does not have disclosed ROE or ROCE figures in the provided data.

Risks & Concerns

No specific risks identified in this filing

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	322.77	31.47	22.31
Q2FY25	349.79	46.7	25.7
Q1FY25	313.36	38.11	25.15
Q4FY24	331	36.53	24.16

The reported revenue of ₹16 Cr in the current filing does not align with the quarterly trend data, which shows revenues in the range of ₹313–₹349 Cr per quarter. This discrepancy suggests that the ₹16 Cr figure may represent a different metric, such as a segmental revenue or a typo. The provided quarterly data spans four consecutive quarters ending Q3FY25, while the filing references Q1FY27. No quarterly data for Q1FY27 is available in the provided context. Therefore, the Quarterly Trend section is based solely on the provided historical quarters and does not include the current filing’s figures due to inconsistency with available data.

📄 View Original Announcement (PDF)

📊 Stock Analysis — METROPOLIS ✨ Ask AI About This